安体舒通联合厄贝沙坦治疗早期糖尿病肾病的疗效分析

目的对安体舒通联合厄贝沙坦治疗糖尿病肾病的疗效进行分析。方法选择2型糖尿病肾病病人64例，常规用药的基础上，治疗组联合应用厄贝沙坦和安体舒通，疗程6个月，观察治疗效果。结果治疗组经治疗后24h尿微量白蛋白定量（UAE）有明显下降，与对照组相比有显著性差异。结论厄贝沙坦和安体舒通联合应用对早期糖尿病肾病有显著疗效肩甚消除或明显减少尿微量白蛋白。可以延缓糖尿病肾病的发展，保护肾功能．安全有效，值得临床推广。

Clinical observation On Irbesartan in Combination with Spironolactone for Treating elderly Patients in early diabetes nephrosis

Objective To explore the therapeutic effect of Irbesartan and Spironolactone in early diabetes nephrosis Methods Sixty-four patients were divideded randomly into two groups： treatment group and comparison group. On the basis of common treatment ,sixty-four patients were treated in Irbesartan and Spironolactone for six months . Results UAE were obviously decreased in treatment groups compaired with comparision groups. Conclusion Irbesartan and Spironolactonecan obviously ehminated or reduced microalbuminuria. And may also continue diabetes nephrosis, It is safe and should be used extensively in clinic.